Cerebrolysin: Porcine Brain-Derived Peptide Mixture

Cerebrolysin is a registered medicine in more than 50 countries (including most of Europe, China, Russia, Mexico, and many Asia-Pacific markets, though notably not the UK, US, Australia or Western European licensing markets such as Germany, France and the Netherlands). It is manufactured by Ever Neuro Pharma in Austria as a standardised low-molecular-weight peptide and amino-acid mixture derived from purified porcine brain proteolysate. It has been used in clinical neurology for more than 40 years for acute ischaemic stroke, traumatic brain injury, vascular dementia, Alzheimer's disease, and severe paediatric developmental conditions. With more than 200 published clinical trials and a substantial Cochrane review evidence base, Cerebrolysin is one of the most clinically validated neurotrophic / neuroprotective therapies in the world — though its lack of approval in major Western regulators reflects ongoing methodological debate.

What is Cerebrolysin?

Cerebrolysin is not a single peptide but a complex, standardised mixture of biologically active low-molecular-weight (<10 kDa) peptides and free amino acids produced by enzymatic breakdown of purified porcine brain. The active fraction is thought to contain peptides that mimic the actions of endogenous neurotrophic factors including BDNF, NGF, CNTF, GDNF and IGF-1. Because it is a complex biological mixture rather than a defined molecular entity, batch-to-batch standardisation is a regulatory concern — Ever Neuro Pharma standardises by total peptide content and bioactivity assays. Each 1 ml ampoule contains 215.2 mg of the peptide concentrate. It is supplied as a clear amber solution for intramuscular or intravenous administration.

• Chemistry: Mixture of low-molecular-weight peptides (<10 kDa) and free amino acids derived from purified porcine brain proteolysate
• Origin: Ever Neuro Pharma (Austria), 1970s; registered in 50+ countries
• Primary route: Intramuscular or intravenous injection only
• Pharmacokinetics: Components have minutes-to-hours plasma half-lives; functional CNS effects persist days after a standard 20-day course.
• Class: Porcine peptide cocktail · Registered medicine

Mechanism of Action

Cerebrolysin acts as a multi-target neurotrophic mimic — its component peptides cross the blood-brain barrier (via specialised peptide transport pathways) and engage receptors for endogenous neurotrophic factors. Documented effects include: upregulation of BDNF and GDNF signalling; promotion of neurogenesis in the subventricular zone and dentate gyrus of the hippocampus; inhibition of caspase-3 mediated apoptosis after ischaemic injury; reduction of beta-amyloid burden in transgenic Alzheimer's models; modulation of microglial activation and neuroinflammation; promotion of dendritic spine density and synapse formation; and a documented "metabolic" effect supporting mitochondrial function under stress. The clinical relevance is that Cerebrolysin produces effects that approximate exogenous neurotrophic factor delivery but with the practical advantage of small peptide components that can actually cross the BBB.

Proposed Benefits

Cerebrolysin has the broadest clinical use-case in this list. Established or actively studied indications include: acute ischaemic stroke (early administration, multiple Phase 3 trials and Cochrane meta-analysis showing modest functional outcome benefit at 90 days, particularly in moderate-to-severe stroke); traumatic brain injury (multiple positive Phase 3 trials including the CAPTAIN trials in moderate-to-severe TBI); vascular dementia (NICE has not endorsed but it is a registered indication in many countries with positive trial evidence); Alzheimer's disease (cognitive stabilisation in mild-to-moderate AD with 30-day courses repeated quarterly); paediatric developmental delay and cognitive disorders; and off-label use in chronic post-concussion syndrome, post-stroke cognitive impairment, and complex regional pain syndrome. Reported subjective effects in nootropic-style use include improved mental clarity, mood lift, and a "clearer head" feeling that builds over a 10-20 day IM course.

Evidence Base

Cerebrolysin has the strongest published clinical evidence base of any compound on this list. Key references: Cochrane review 2017 (Ziganshina et al.) on Cerebrolysin in acute ischaemic stroke, including data from 1,773 patients, finding evidence of benefit in moderate-to-severe stroke with no significant safety concerns; CAPTAIN I and CAPTAIN II Phase 3 TBI trials showing improved functional outcomes; multiple Phase 3 vascular dementia trials (Guekht et al., 2011; Muresanu et al., 2008); Alzheimer's trials (Alvarez et al., 2011, 2016). The body of evidence is large, but Western regulatory non-approval reflects concerns about methodological quality, blinding integrity, and result heterogeneity across geographies. The compound has not failed a major safety hurdle — it has not yet cleared the methodological bar required for FDA or NICE approval.

Dosage & Administration

Clinical doses (registered indications, under medical supervision): Acute stroke — 30-50 ml IV daily for 10-21 days starting within 24 hours of onset; TBI — 30-50 ml IV daily for 10-30 days; dementia — 10-30 ml IM or IV daily for 20 days, repeated quarterly. Community / nootropic protocols: typically a 20-day course of 5-10 ml IM daily, repeated 1-2 times per year. Cerebrolysin must be injected — there is no oral, sublingual, transdermal, or intranasal route. Standard practice is glute or thigh IM injection; IV is used in hospital settings for higher doses. Pre-filled ampoules (1, 2, 5, 10 ml) are sold throughout Europe and Asia. The 20-day course is the typical clinical and community-protocol unit; effects are not acute but cumulative over the course.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Cerebrolysin's safety record across 40+ years and millions of doses is reassuring but the injectable route introduces practical risks. Reported acute effects: injection site reactions (most common, particularly with IM), transient flushing or warmth, mild dizziness or feeling lightheaded if injected too rapidly IV, occasional palpitations, very rare allergic / anaphylactic reactions, and rare reports of seizure (in patients with epilepsy on rapid IV infusion). Contraindications: known hypersensitivity to porcine proteins (it is a porcine product — a real concern for some religious / dietary practices), status epilepticus, severe renal impairment, pregnancy/breastfeeding (data sparse), and concurrent MAOI use. Theoretical concern about porcine-origin transmissible spongiform encephalopathies has been addressed by the manufacturer's purification process; there are no documented transmission cases.

UK Legal Status

Cerebrolysin's UK legal position is unusual: it is not a controlled substance under the Misuse of Drugs Act 1971 and not scheduled under the Psychoactive Substances Act 2016, but it is also not licensed as a medicine by the MHRA despite being a registered medicine in many other European countries. This places it in a legal grey area — importing for personal use from licensed European pharmacies (where it is a prescription medicine) is generally tolerated under personal import allowances, but commercial sale within the UK for human use is not lawful. It cannot be prescribed on the NHS. WADA: not on the Prohibited List. US: not FDA-approved, treated as an unapproved drug for human use.

Cerebrolysin vs Dihexa

Cerebrolysin is the closest mechanistic parallel to Dihexa among the compounds in this list — both promote neurotrophic signalling, both are presumed to drive synaptic plasticity, and both have been studied in dementia / stroke / TBI contexts. Differences are practical and operational rather than purely mechanistic. Cerebrolysin is a defined clinical medicine with 40 years of trial data, manufactured to GMP standards, administered IM or IV under medical supervision in 20-day courses. Dihexa is a single defined peptide (vs Cerebrolysin's mixture), orally bioavailable (vs injection-only), with substantially less human clinical data, and acts via a specific HGF/c-Met pathway rather than the broad neurotrophic mimicry of Cerebrolysin. For serious neurological indications where access to clinical care is available, Cerebrolysin has the stronger evidence and regulatory profile. For research-chemical-context cognitive enhancement, Dihexa's oral route and defined target are more practical.

Stacking with Dihexa

Cerebrolysin is rarely stacked with research-chemical peptides in the same way Semax or Selank are, because of the practical demands of the injection route and the structured 20-day course format. Within clinical practice it is often combined with standard care (anticoagulants post-stroke, cholinesterase inhibitors in AD, neurorehabilitation programmes). In nootropic-style use some users run a Cerebrolysin course alongside their normal Dihexa, Semax, or Selank protocols — there is no published interaction data but mechanisms are non-competitive. Cerebrolysin + Dihexa is potentially complementary (broad neurotrophic plus targeted synaptogenic), though it amounts to a substantial pharmacological intervention and should be discussed with a healthcare professional given Cerebrolysin's registered-medicine status.

Frequently Asked Questions

The Bottom Line

Cerebrolysin is the most clinically validated neurotrophic therapy currently available, with 40+ years of registered medical use across stroke, TBI and dementia indications in more than 50 countries. Its injection-only delivery and porcine origin are practical limitations, and its lack of UK / US / Western-European regulatory approval reflects methodological debate rather than safety failure. Mechanistically it is the closest peer to Dihexa among nootropic-adjacent compounds. For users seeking a structured, course-based intervention with the strongest clinical evidence base, Cerebrolysin is the leading option — though Dihexa's oral route and single-target precision serve a different practical niche.

Related reading: Dihexa vs Other Nootropics overview · Dihexa Mechanism of Action · Dihexa Dosage Guide · Dihexa Side Effects & Risks · UK Legal Status